Yuesai Biotech develops cellular therapies utilizing human induced pluripotent stem cells (hiPSCs) to provide treatment options for neurodegenerative diseases and rare disorders. The company employs advanced technologies such as reprogramming, stem cell differentiation, and high-precision gene editing to address significant unmet medical needs in these areas.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases and rare disorders lack effective treatments, creating a significant unmet medical need for patients suffering from these conditions. Current therapeutic options often fail to address the underlying causes of disease progression, offering only symptomatic relief.
Solution
Yuesai Biotech is developing cell-based therapies using human induced pluripotent stem cells (hiPSCs) to address neurodegenerative diseases and rare disorders. The company leverages reprogramming, stem cell differentiation, SISBAR lineage tracing, and high-precision gene editing platforms to create novel treatments. Their approach focuses on developing therapies that can modify disease progression and offer long-term benefits for patients with limited or no existing treatment options. The company has a pipeline of five therapeutic candidates centered around neurodegenerative diseases.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases and rare disorders, as well as clinicians and researchers seeking innovative treatment options for these conditions.
Features
- hiPSC reprogramming technology for generating high-quality stem cells
- Stem cell differentiation platform for producing specific cell types relevant to target diseases
- SISBAR lineage tracing technology for monitoring cell fate and therapeutic efficacy
- High-precision gene editing platform for modifying cells to enhance therapeutic potential
- Pipeline of five therapeutic candidates focused on neurodegenerative diseases